JP2025508016A5 - - Google Patents
Info
- Publication number
- JP2025508016A5 JP2025508016A5 JP2024552797A JP2024552797A JP2025508016A5 JP 2025508016 A5 JP2025508016 A5 JP 2025508016A5 JP 2024552797 A JP2024552797 A JP 2024552797A JP 2024552797 A JP2024552797 A JP 2024552797A JP 2025508016 A5 JP2025508016 A5 JP 2025508016A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- kit
- leukemia
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263316680P | 2022-03-04 | 2022-03-04 | |
| US63/316,680 | 2022-03-04 | ||
| PCT/US2023/063669 WO2023168394A1 (en) | 2022-03-04 | 2023-03-03 | Methods of treating cancer with iap antagonist compounds and combination therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508016A JP2025508016A (ja) | 2025-03-21 |
| JP2025508016A5 true JP2025508016A5 (enExample) | 2026-03-12 |
Family
ID=85792184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552797A Pending JP2025508016A (ja) | 2022-03-04 | 2023-03-03 | Ｉａｐアンタゴニスト化合物を用いたがんの治療方法及び併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250186451A1 (enExample) |
| EP (1) | EP4486352A1 (enExample) |
| JP (1) | JP2025508016A (enExample) |
| KR (1) | KR20240156407A (enExample) |
| AU (1) | AU2023229084A1 (enExample) |
| TW (1) | TW202345849A (enExample) |
| WO (1) | WO2023168394A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122022015241B1 (pt) | 2013-12-20 | 2023-09-26 | Astex Therapeutics Limited | Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i) |
| CN120379671A (zh) * | 2022-10-18 | 2025-07-25 | 辉瑞公司 | 用于治疗癌症的化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| BR122022015241B1 (pt) | 2013-12-20 | 2023-09-26 | Astex Therapeutics Limited | Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i) |
| GB201919219D0 (en) * | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
-
2023
- 2023-03-03 KR KR1020247033050A patent/KR20240156407A/ko active Pending
- 2023-03-03 JP JP2024552797A patent/JP2025508016A/ja active Pending
- 2023-03-03 US US18/843,651 patent/US20250186451A1/en active Pending
- 2023-03-03 EP EP23714443.1A patent/EP4486352A1/en active Pending
- 2023-03-03 AU AU2023229084A patent/AU2023229084A1/en active Pending
- 2023-03-03 WO PCT/US2023/063669 patent/WO2023168394A1/en not_active Ceased
- 2023-03-03 TW TW112107831A patent/TW202345849A/zh unknown